leisure time -WSS

leisure time

author：Wikipedia 2025-08-19 15:01:32 - browse：9

Adam's take main illustration — Molly Ferguson/STAT

For two days starting on Sunday, Moonlake Immunotherapeutics happily crunched numbers and shared results from a mid-stage clinical trial that depicted its experimental antibody in the most flattering terms possible.

The drug, called sonelokimab, was “changing the game” for the treatment of a debilitating skin condition called hidradenitis suppurativa, or HS, said Moonlake CEO Jorge Santos da Silva, on a call for investors and analysts. The drug’s benefit for patients placed it “at the top of the heap,” he added.

For other, equally important data from the same study that did not fit Moonlake’s home-run narrative, the company took a DIY approach. Curious about how sonelokimab performed against a treatment that’s already approved for HS? Pull out a calculator and do the math yourself. How badly did a higher dose of the drug underperform a lower dose? Take a guess.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Dobbs anniversary: the lost opportunity of abortion as health care
Next article： FDA early review: GLP

focus

leisure time

WSS

Why Talkspace is targeting Medicare, a tricky market

Stem cell biologist probes earliest stages of human development

$1 billion proposal to grow Boston, Massachusetts biotech

Ancient Greek ideas underpin modern concepts of pregnancy

Medicare drug price negotiation hearing pits pharma v Biden admin

Rune Labs, whose app tracks Parkinson's symptoms, raises $12M

hotspot

leisure time

hotspot

Anesthesiologist group: stop taking Ozempic before surgery

Florida health officials providing scant details on measles cases

23andMe had bad news about my health. I wish a person had delivered it

Stem cell biologist probes earliest stages of human development

Guidelines to prevent youth baseball injuries need more muscle

Stem cell biologist probes earliest stages of human development

How to save PrEP access — and even expand it

Microsoft's Peter Lee: Generative AI could help doctors be more human

Medicare proposal to cover medical devices draws a mixed reaction

$1 billion proposal to grow Boston, Massachusetts biotech

entertainment

Microsoft's Peter Lee: Generative AI could help doctors be more human

JPM pitch from hospitals? Revenue streams outside of patient care

State of the Union pitch: Bigger Medicare drug price negotiations

Readout Newsletter: BridgeBio, Akero, and human embryo models

American taxpayers paid $1.8 trillion in health care costs in 2022

Medicare Advantage overpayments discussion gets experts fired up

leisure time

focus

leisure time

entertainment